Zobrazit v EDS

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP)

Uloženo v:
Podrobná bibliografie
Název: Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP)
Autoři: Ciaffi, Laura, Koulla-Shiro, Sinata, Sawadogo, Adrien Bruno, Ndour, Cheik Tidiane, Eymard-Duvernay, Sabrina, Mbouyap, Pretty Rosereine, Ayangma, Liliane, Zoungrana, Jacques, Gueye, Ndeye Fatou Ngom, Diallo, Mohamadou, Izard, Suzanne, Bado, Guillaume, Kane, Coumba Toure, Aghokeng, Avelin Fobang, Peeters, Martine, Girard, Pierre Marie, Le Moing, Vincent, Reynes, Jacques, Delaporte, Eric, Calmy, Alexandra
Zdroj: The Lancet HIV, Vol. 4, No 9 (2017) pp. e384-e392
Informace o vydavateli: 2017.
Rok vydání: 2017
Témata: ddc:616, Adult, Male, Highly Active/methods, Combination/methods, Anti-HIV Agents/administration & dosage/economics/therapeutic use, HIV Infections/drug therapy/epidemiology/virology, Lamivudine/administration & dosage/therapeutic use, Antiretroviral Therapy, Cameroon/epidemiology, HIV Protease Inhibitors/administration & dosage/therapeutic use, Middle Aged, Africa South of the Sahara/epidemiology, Viral Load/drug effects, CD4 Lymphocyte Count, Drug Therapy, Senegal/epidemiology, HIV-1, Humans, Female, Reverse Transcriptase Inhibitors/administration & dosage/therapeutic use
Popis: Despite satisfactory efficacy of WHO-recommended second-line antiretroviral treatment for patients with HIV in low-income countries, the need for simplified, low-cost, and less-toxic maintenance strategies remains high. We compared boosted protease inhibitor monotherapy with dual therapy with boosted protease inhibitor plus lamivudine in patients on second-line antiretrovial therapy (ART).
Druh dokumentu: Article
Popis souboru: application/pdf
Jazyk: English
DOI: 10.1016/s2352-3018(17)30069-3
Přístupová URL adresa: https://archive-ouverte.unige.ch/unige:112376
Přístupové číslo: edsair.dedup.wf.002..a8b56a9b73adc7fcbe5c10f63493a325
Databáze: OpenAIRE
Popis
Abstrakt:Despite satisfactory efficacy of WHO-recommended second-line antiretroviral treatment for patients with HIV in low-income countries, the need for simplified, low-cost, and less-toxic maintenance strategies remains high. We compared boosted protease inhibitor monotherapy with dual therapy with boosted protease inhibitor plus lamivudine in patients on second-line antiretrovial therapy (ART).
DOI:10.1016/s2352-3018(17)30069-3